Wayne Burton, MD, former global corporate medical director for American Express, discusses what he views as the key takeaways from a migraine peer exchange he recently participated in.
Transcript:
You recently participated in a peer exchange discussion on migraine. What were some key takeaways from that conversation?
There were a number of highlights and takeaways from the peer exchange. We realized that migraine now affects more than 40 million Americans; many of them, [a] large number— perhaps over 40%– are not diagnosed or are misdiagnosed and there’s lots of opportunities now with new treatments especially for episodic and chronic patients with migraine.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More